Education
About Us
Working with TipRanks
Follow Us
Fresenius SE & Co (FSNUY)
OTHER OTC:FSNUY
Top Page
Fresenius SE & Co
(OTC:FSNUY)
Rating:67Neutral
Price Target:
$14.50
▲(6.70% Upside)
Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.88B
Dividend Yield2.03%
Average Volume (3M)2.62K
Price to Earnings (P/E)24.7
Beta (1Y)0.24
Revenue Growth<0.01%
EPS GrowthN/A
CountryUS
Employees175,202
SectorHealthcare
Sector Strength50
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.25
Shares Outstanding2,252,949,200
10 Day Avg. Volume4,892
30 Day Avg. Volume2,616
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit7.88
Enterprise Value/Ebitda13.16
Forecast
1Y Price Target
$14.32Price Target Upside5.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Fresenius SE & Co Business Overview & Revenue Model
Company DescriptionFresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
How the Company Makes MoneyFresenius generates revenue through multiple key streams. The largest segment, Fresenius Medical Care, earns revenue by providing dialysis treatments, equipment, and related services to patients with chronic kidney failure around the world. This segment benefits from a large patient base and long-term contracts with healthcare providers. Fresenius Helios contributes significantly to revenue through the operation of private hospitals in Germany, where it receives payments for medical services provided to patients. Fresenius Kabi adds to the revenue through the sale of generic pharmaceuticals, intravenous solutions, and medical devices, capitalizing on the growing demand for healthcare products. Additionally, strategic partnerships and acquisitions enhance its market position and revenue potential, allowing Fresenius to expand its service offerings and geographic reach.
Fresenius SE & Co Earnings Call Summary
Earnings Call Date:Aug 06, 2025
(Q2-2025)
| % Change Since: 13.44%|
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Neutral
Fresenius demonstrated strong performance and raised revenue guidance due to robust growth in key segments like Kabi and Biopharma. However, challenges remain, particularly in China and with currency and tariff headwinds. The sentiment reflects a cautiously optimistic outlook, balancing strong achievements with ongoing challenges.Q2-2025 Updates
Positive Updates
Guidance Raise and Resilient Performance
Fresenius raised its full-year organic revenue guidance from 4%-6% to 5%-7% due to strong top-line growth. The company reported an 8% core EPS growth, with 10% growth in the first half of the year.
Strong Kabi Performance
Kabi achieved a 16.4% EBIT margin, driven by strong performance in IV generics and fluids, and biosimilars. The segment launched 6 new IV generic products in the U.S. and reported 40% organic growth in its cell and gene therapy segment.
Biopharma Achievements
Fresenius Kabi launched a denosumab biosimilar in the U.S. and received EU regulatory approval. The biosimilar Tyenne gained 24% market share in EU5 and was approved in Brazil.
Helios Strategic Advancements
Helios continued its clustering strategy in Germany and was part of a government-approved EUR 4 billion financial support for hospitals.
Negative Updates
Challenges in China
The nutrition business in China faced adverse impacts due to the Keto tender loss as part of VBP, with a mid-double-digit million revenue impact expected quarterly.
FX and Tariff Headwinds
The company reported negative effects from currency translation and potential impacts from U.S. tariffs, which are expected to materialize in the second half of the year.
Flattish EBIT Development
Helios faced challenges with prior year energy relief payments and the Easter effect, leading to a flattish EBIT development at constant currency.
Company Guidance
During the Fresenius earnings call for the second quarter of fiscal year 2025, the company reported strong financial performance, highlighted by an 8% growth in core EPS and a notable 10% increase in core EPS for the first half of the year. The company's full-year organic revenue guidance was raised from 4%-6% to 5%-7%, driven by robust top-line growth. Fresenius Kabi's EBIT margin was reported at 16.4%, and Helios demonstrated solid organic growth of 5%. The company's strategic initiatives, including the #FutureFresenius program, are contributing to increased profitability and margin expansion. The call also underscored the company's focus on sustainability, reflected in an improved ISS ESG rating. Additionally, the company highlighted its positive progress in the biopharma segment and successful new product launches in the U.S. and Europe. Despite macroeconomic volatility and geopolitical tensions, Fresenius remains confident in its strategic direction and financial outlook.Fresenius SE & Co Financial Statement Overview
Summary
Fresenius SE & Co's financial health is underscored by solid operational margins and an effective balance sheet structure, supported by strong cash flow management. However, challenges in net income margins and erratic revenue growth affect the score.Income Statement
The income statement reveals a mixed performance. Gross profit margin for TTM (Trailing-Twelve-Months) is healthy at 24.48%, and EBIT margin is 8.65%, indicating operational efficiency. However, the net profit margin is modest at 1.91%, highlighting challenges in translating revenue into profit. Revenue growth has been erratic, with a decline in recent years, affecting overall score.65
Positive
Balance Sheet
The balance sheet shows strength in equity with an equity ratio of 44.91%. The debt-to-equity ratio stands at 0.70, suggesting a balanced capital structure. However, the return on equity (ROE) is low at 2.17%, indicating limited effectiveness in generating returns on invested capital.70
Positive
Cash Flow
The cash flow statement is robust, with a strong operating cash flow to net income ratio of 6.19, indicating effective conversion of income into cash. Free cash flow growth is notable, and the free cash flow to net income ratio is 3.95, highlighting efficient cash management practices. Nevertheless, recent fluctuations in free cash flow growth suggest potential volatility.72
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.83B | 22.30B | 40.84B | 37.52B | 36.28B |
| Gross Profit | 5.38B | 5.06B | 10.72B | 10.31B | 10.32B |
| EBITDA | 3.14B | 2.73B | 3.09B | 6.84B | 7.19B |
| Net Income | 471.00M | -594.00M | 1.37B | 1.82B | 1.71B |
Balance Sheet | |||||
| Total Assets | 43.55B | 45.28B | 76.42B | 71.96B | 66.65B |
| Cash, Cash Equivalents and Short-Term Investments | 2.05B | 2.56B | 2.35B | 2.75B | 2.00B |
| Total Debt | 13.58B | 15.83B | 27.76B | 27.16B | 25.91B |
| Total Liabilities | 23.26B | 25.63B | 44.20B | 42.67B | 40.62B |
| Stockholders Equity | 19.54B | 19.00B | 20.41B | 19.00B | 16.95B |
Cash Flow | |||||
| Free Cash Flow | 1.52B | 3.32B | 2.28B | 3.03B | 4.14B |
| Operating Cash Flow | 2.45B | 4.46B | 4.20B | 5.08B | 6.55B |
| Investing Cash Flow | -510.00M | -3.19B | -2.61B | -2.82B | -3.01B |
| Financing Cash Flow | -2.18B | -1.38B | -1.60B | -1.45B | -3.12B |
Fresenius SE & Co Technical Analysis
Positive
13.59
Price Trends
12.41
Positive
11.89
Positive
10.59
Positive
Market Momentum
0.32
Negative
77.42
Negative
99.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 13.59 is above the 20-day moving average (MA) of 12.51, above the 50-day MA of 12.41, and above the 200-day MA of 10.59, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 77.42 is Negative, neither overbought nor oversold. The STOCH value of 99.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $11.36B | 9.40 | 18.66% | 0.45% | 9.61% | 39.65% | |
75 Outperform | $15.20B | 10.97 | 41.09% | ― | -1.09% | -43.10% | |
73 Outperform | $12.13B | 23.54 | 25.35% | 0.57% | 11.80% | 30.02% | |
70 Outperform | $14.64B | 20.44 | 4.72% | 3.17% | 1.11% | 25.84% | |
67 Neutral | $29.88B | 24.69 | 7.06% | 2.03% | <0.01% | ― | |
65 Neutral | ¥343.60B | 11.39 | -0.17% | 2.39% | 9.60% | -12.34% | |
60 Neutral | $9.68B | 13.09 | 635.30% | ― | 5.09% | 7.85% |
* Healthcare Sector Average
Performance Comparison
FSNUY
Fresenius SE & Co
13.59
4.81
54.78%
DVA
DaVita
133.25
-14.33
-9.71%
FMS
Fresenius Medical Care
24.84
6.52
35.59%
EHC
Encompass Health
122.14
34.10
38.73%
THC
Tenet Healthcare
171.33
16.11
10.38%
UHS
Universal Health
177.61
-49.03
-21.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.